Novartis Investor Presentation
New Novartis: Our strategy
Our focus
> Core Therapeutic Areas
Technology platforms
Priority geographies
Capital allocation / structure
Our priorities
Conclusion
Abbreviations
Focused on 5 core Therapeutic Areas...
Select examples
Cardiovascular
Disease
areas
■ Heart failure & hypertension
■ Atherosclerosis
Commercial
assets
Entresto*
sacubitril/valsartan
LEQVIO®
Immunology
■ Psoriasis
■ Psoriatic arthritis
◉
Spondylitis/Spondylarthritis
■ Hidradenitis suppurativa
■ CSU
Sjögren's / SLE/LN
Cosentyx
secukinumab
ILARIS
(canakinumab)
150 mg subcutaneous injection
9
Neuroscience
◉
Multiple sclerosis
◉
Spinal muscular atrophy
Neurodegeneration, incl.
Huntington's, Parkinson's, ALS
Kesimpta
(ofatumumab)
MAYZENT.
(siponimod) tablets
GILENYA
(fingolimod)
Capsules
Solid Tumors
Breast and Women's cancer
■ Prostate cancer
◉
Lung cancer
1. Core TAs
Hematology
■
Non-Hodgkin's lymphoma
Non-malignant hematological -
Immune thrombocytopenia
■ Acute myeloid leukemia /
Myelodysplastic syndrome
zolgensma
Taimovig
(erenumab-acce
KISQALI PLUVICTO™
ribociclib
Tafinlar + Mekinist
(dererle niby
PIQRAY*
(alpelisib) tablets
(trainelinib)
Advanced LUTATHERA
KYMRIAH
(tisagenlecleucel)
SCEMBLIX®
(asciminib) 20 mg. 40 mg tablets
PROMACTA JAKAVI
(eltrombopag)
ruxolitinib
Pipeline
assets and
opportunities
Iptacopan (LNP023)
C3G, IgAN
Pelacarsen (TQJ230)
CVRR-Lp(a)
Leqvio
CVRR-LDLC
Cosentyx
Multiple indications
Remibrutinib (LOU064)
CSU
lanalumab (VAY736)
Sjögren's, SLE, LN
Ligelizumab (QGE031)
Food Allergy
Remibrutinib (LOU064)
MS
Zolgensma (AVXS-101 IT)
SMA IT
Branaplam (LMI070)
Huntington's
Kisqali
Adjuvant HR+/HER2- BC
TNO155, JDQ433
NSCLC; Colorectal Cancer; Combos
NIS793
1L MPDAC / 1L MCRC
Iptacopan (LNP023)
PNH, aHUS
Sabatolimab (MBG453)
MDS, AML
lanalumab (VAY736)
Multiple indications
YTB323
DLBCL
TA-x (incl. Ophtha, Resp and other assets) not included in the above list. Pelacarsen is licensed from lonis Pharmaceuticals, Inc.
6
Novartis Investor Presentation | September 22, 2022
&
NOVARTIS | Reimagining MedicineView entire presentation